Weight Loss Medications: FAQs
Weight Loss Medications: Semaglutide, Tirzepatide, and Related Drugs (FAQs)
Weight loss medications have changed what is possible for many patients with obesity and related metabolic disease. The most widely used prescription options today work by targeting gut hormone pathways that regulate appetite, satiety, gastric emptying, and insulin signaling. Below are answers to common questions we get in primary care.
What are these medications, in plain English?
These are prescription medications that help reduce appetite and improve metabolic regulation by mimicking (or targeting) incretin hormones. The two best-known drug families are:
GLP-1 receptor agonists (example: semaglutide)
Dual incretin agonists (example: tirzepatide, which targets GLP-1 plus another pathway)
They were initially developed for type 2 diabetes, and specific versions are approved for chronic weight management in eligible patients.
What are the brand names people usually recognize?
Common brand names include Wegovy/Ozempic (semaglutide) and Zepbound/Mounjaro (tirzepatide). These names are often used interchangeably online, but the approved indication and dosing can differ by product.
Who are these medications for?
In general, these medications are considered for adults with:
Obesity, or
Overweight plus weight-related medical conditions (for example: high blood pressure, sleep apnea, prediabetes, type 2 diabetes, fatty liver disease)
Eligibility and coverage depend on your medical history and your insurance plan’s rules.
How much weight loss is typical in the major clinical trials?
Results vary by medication, dose, and the population studied, but large randomized trials show substantial average weight loss in people with obesity.
Semaglutide 2.4 mg (STEP 1 trial): average weight loss around 15% over ~68 weeks in adults with overweight/obesity (without diabetes).
Tirzepatide (SURMOUNT-1 trial): average weight loss roughly 15% to 21%, depending on dose, over ~72 weeks in adults with obesity/overweight.
Real-world outcomes can be lower than trials if people cannot reach or sustain effective doses, stop early due to side effects, or run into cost/coverage barriers.
Are these “forever drugs”?
They are best thought of as chronic disease medications for many patients, not short-term cosmetic tools. If someone stops the medication, appetite signaling often returns toward baseline and weight regain is common unless there is a durable plan in place.
What are the most common side effects?
The most common are gastrointestinal:
Nausea
Fullness or reduced appetite
Constipation
Diarrhea
Reflux or indigestion
Most side effects are dose-related and can improve with slow dose escalation, hydration, fiber, protein intake, and individualized adjustments.
What are the serious risks people should know about?
These are uncommon, but important:
Gallbladder disease (gallstones, gallbladder inflammation)
Pancreatitis (rare; evaluation is needed if severe, persistent abdominal pain occurs)
Dehydration-related kidney stress if vomiting or diarrhea is significant, especially in people with underlying kidney disease
A boxed warning exists for thyroid C-cell tumors based on rodent findings; these medications are typically avoided in people with a personal or family history of medullary thyroid cancer or MEN2 (your clinician will screen for this).
Medication interactions can matter too: because these drugs slow stomach emptying, they can affect absorption timing for some oral medications.
Do these medications have benefits beyond the number on the scale?
There is strong evidence that weight loss from these medications can improve metabolic health markers (blood sugar, blood pressure, triglycerides, liver fat in many patients). For “hard outcomes,” evidence is evolving and differs by population.
One of the most important recent developments is cardiovascular risk reduction: the FDA expanded Wegovy’s indication to include reducing the risk of major cardiovascular events in certain adults with established cardiovascular disease and obesity/overweight.
Other areas being actively studied include kidney outcomes, inflammation markers, sleep apnea, and more. Some signals look promising, but not every question is fully settled yet.
What about claims like “brain benefits” or dementia prevention?
You may see headlines suggesting lower dementia or stroke risk. Some early data are observational or secondary analyses. That means they can be hypothesis-generating, but they are not the same as definitive proof of prevention. This is an area to watch, but it should be discussed carefully and without overclaiming.
Do these medications affect visceral fat and inflammation?
Weight loss tends to reduce visceral (deep abdominal) fat, which is strongly linked to cardiometabolic risk. Many studies also show improvements in inflammatory markers as metabolic health improves. The degree varies by patient and by overall weight change.
Does insurance cover these medications?
Coverage is highly plan-specific. Common patterns:
Diabetes indications are more likely to be covered than weight-loss-only indications.
Many plans require prior authorization, documentation of BMI and comorbidities, and sometimes proof of participation in lifestyle efforts.
Some employers and plans explicitly exclude weight-loss drugs.
We typically advise patients to assume coverage is uncertain until we verify your specific plan details.
Which is “better,” semaglutide or tirzepatide?
In head-to-head and cross-trial comparisons, tirzepatide often shows greater average weight loss at higher doses. But “better” depends on:
Side effect tolerance
Coexisting conditions (for example: type 2 diabetes, kidney disease, reflux, constipation tendency)
Contraindications and medication interactions
Coverage and affordability
The dose you can realistically reach and sustain
The best medication is the one that is safe for you, you can tolerate, and you can stay on long enough to benefit.
What about compounded versions of these medications?
This is a fast-moving area. Patients should be cautious: quality, dosing consistency, and source transparency matter. We generally recommend prioritizing FDA-approved products when feasible and discussing risks carefully if alternatives are considered.
I’m on HRT. Does that change anything?
There is active discussion and emerging research around menopause, hormone therapy, and metabolic response. One practical point is that these medications can slow gastric emptying, which may affect absorption timing of some oral medications. If you are on HRT (especially oral progesterone), it is worth reviewing your regimen with a clinician.
What does a safe, medical approach look like in a primary care setting?
A medical approach typically includes:
Confirming eligibility and reviewing medical history
Screening for contraindications and medication interactions
Choosing a medication and dose-escalation strategy
Monitoring response, side effects, and key health markers over time
Building a plan for nutrition, strength training, sleep, and long-term maintenance
Important note
This page is for general education and is not medical advice. These medications should be used under clinician supervision, with individualized risk-benefit discussion.
